Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis — Stella

Home/Primary Myelofibrosis (PMF)/Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

View on ClinicalTrials.gov

Recruiting

Back to Primary Myelofibrosis (PMF) trials

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Hong Kong

Department of Medicine, Queen Mary Hospital, Hong Kong

Key details

Phase

Safety & dosing

Sponsor

The University of Hong Kong

Enrollment target

~20 participants

Started

March 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.